Peptide Library

Human study PLS-00200

From proteomic multimarker profiling to interesting proteins: thymosin-β(4) and kininogen-1 as new potential biomarkers for inflammatory hepatic lesions.

Case-control study · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • From proteomic multimarker profiling to interesting proteins: thymosin-β(4) and kininogen-1 as new potential biomarkers for inflammatory hepatic lesions.primary · Journal of cellular and molecular medicine · 2011-10-01 · PMID 21496200 · DOI

Design and participants

Design
Case-control study
Population
Patients chronically infected with hepatitis C virus (179 serum samples) and control sera (195 samples)
Conditions
Chronic hepatitis C, Liver fibrosis/cirrhosis
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported
Funding
Research Support, Non-U.S. Gov't (per publication type); funder not named in record

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Kininogen-1 and thymosin β4 were identified as potential new serum biomarkers for chronic hepatitis C. Serum proteomic profiling is a reliable way to detect hepatitis-associated patterns, and the panel needs validation in larger cohorts.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Thymosin β4 was measured only as an endogenous serum biomarker and was never administered to participants.
    • abstract only: Only the abstract is available in the record, so methods and full results cannot be verified.
    • inappropriate endpoint: Thymosin β4 was measured as a diagnostic biomarker, not given as a treatment, so there are no efficacy or safety outcomes.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 21496200, abstract (final two sentences) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 21496200, abstract (sentence 3) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 21496200, abstract (sentences 3 and 8) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 21496200, abstract (sentence 3) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).